Two more deaths reported from Natrecor study

01/3/2006 | ABC News

Johnson & Johnson unit Scios reported two additional deaths occurred during a study of its heart failure drug Natrecor three years ago, but the company said the cases do not indicate increased risk from the drug. A total of seven patients died within 30 days of treatment with Natrecor. The company is preparing a report for the FDA due by April, and the authors of a report on the original study published in the October 2005 issue of the Journal of Emergency Medicine will update their report.

View Full Article in:

ABC News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ